Sinusitis News and Research

Latest Sinusitis News and Research

Ethicon and Acclarent announce definitive merger agreement

Ethicon, Inc., a Johnson & Johnson company and a worldwide leader in surgical care, and Acclarent, Inc., a privately held medical technology company dedicated to designing, developing and commercializing devices that address conditions affecting the ear, nose and throat (ENT), today announced a definitive merger agreement whereby Ethicon will acquire Acclarent in an all-cash transaction for approximately $785 million net of estimated cash on hand at time of closing.

17 Dec 2009

Florida doctor performs new, effective treatment for sinusitis

Local physician William Laskowski, MD has become the first doctor in Florida to perform an effective new treatment for sinusitis called FinESS® Sinus Treatment in an office setting. FinESS® (Entellus Medical, Maple Grove, MN) is a balloon sinuplasty option that is less-invasive than traditional sinus surgery and breaks the cycle of chronic or recurrent sinusitis with immediate relief and lasting results.

15 Dec 2009

Texas Sinus Center offers FinESS Sinus Treatment to break the cycle of chronic sinusitis

Dr. James Atkins, founder of the Texas Sinus Center (www.texassinuscenter.com), today announced he is now offering the FinESS® Sinus Treatment, a minimally invasive treatment that breaks the cycle of chronic sinusitis (CRS) at Foundation Surgical Hospital of San Antonio.

8 Dec 2009

Researchers identify gene expression and biological pathways for healing gingivitis

Gingivitis, which may affect more than one-half of the U.S. adult population, is a condition commonly attributed to lapses in simple oral hygiene habits. However, a new study shows that development and reversal of gingivitis at the molecular level is apparently much more complicated than its causes might indicate.

8 Dec 2009

Study shows herbal medicine is effective for treating acute rhinosinusitis

Rhinosinusitis is an inflammatory process involving one or more of the paranasal sinuses that typically follows a viral upper respiratory tract infection (RTI). The term ‘acute rhinosinusitis’ is used instead of ‘acute sinusitis’ because it is the currently internationally accepted terminology.

4 Dec 2009

SinoFresh Healthcare re-launches sales and distribution of Sinofresh Nasal Spray

SinoFresh Healthcare, Inc. over the last six months has re-launched sales and distribution of the Sinofresh Nasal Spray product through the exclusive licensee of the products through, Sinofresh Healthcare Products, Inc., a privately held company.

2 Dec 2009

New target may promote development of novel therapies for chronic sinusitis

A protein known to stimulate blood vessel growth has now been found to be responsible for the cell overgrowth in the development of polyps that characterize one of the most severe forms of sinusitis, a study by Johns Hopkins researchers suggests. The finding gives scientists a new target for developing novel therapies to treat this form of the disease, which typically resists all current treatments.

23 Nov 2009

Entellus Medical completes its Series D financing totaling $30MM

Entellus Medical, the Minnesota-based developer of novel, less invasive treatments for chronic conditions of sinusitis, has completed its Series D financing totaling $30MM. The Series D round was led by new investor Essex Woodlands Health Ventures and supported by existing investors Split Rock Partners and SV Life Sciences.

17 Nov 2009

Treatment of allergic rhinitis can improve nasal and ocular symptoms

The treatment of allergic rhinitis is shown to improve co-existing conditions including conjunctivitis, asthma, sinusitis, otitis media with effusion (fluid in the middle ear) and sleep disorders according to an international expert at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Miami Beach, Fla.

10 Nov 2009

Study of combination therapy versus monotherapy for pulmonary arterial hypertension

Gilead Sciences, Inc., in collaboration with GlaxoSmithKline (GSK), today announced plans for an international, event-driven (morbidity and mortality) clinical trial to study combination therapy versus monotherapy in a first-line treatment setting for pulmonary arterial hypertension (PAH).

2 Nov 2009

Boehringer Ingelheim Pharmaceuticals receives NDA approval from FDA for its Micardis Tablets 80 mg

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) inhibitors.(1) MICARDIS is the most studied ARB in this high-risk patient population and has been commercially available to treat hypertension (high blood pressure) since its approval in 1998.

19 Oct 2009

Bad breath can be treated

All of us have experienced bad breath at some point. However, suffering from chronic bad breath, or halitosis, can be embarrassing and affect your self-esteem and relationships with family, friends and coworkers. The good news -- bad breath is often preventable and easily treated.

12 Oct 2009

Patients with chronic rhinosinusitis also suffer from asthma and hypertension

Patients who suffer from chronic rhinosinusitis (CRS) also tend to suffer from other chronic illnesses, like asthma, hypertension, and arthritis.

5 Oct 2009

New website offers personalized advice on H1N1

Researchers at the University of Southampton have developed a new website which gives personalised advice on coping with swine flu and other cold and flu symptoms.

1 Oct 2009

New treatment for chronic sinusitis from Summit Ear, Nose & Throat

Summit Ear, Nose & Throat is the first in the area to offer an exciting new treatment for chronic sinusitis (CRS) in an outpatient setting called FinESS™ Sinus Treatment. FinESS is a new balloon sinuplasty technique that is less invasive than traditional sinus surgery and that breaks the cycle of chronic sinusitis with immediate relief and lasting results.

30 Sep 2009

Phase II VICTOR-E1 clinical study results reported

Schering-Plough Corporation today reported long-term data with vicriviroc, its investigational CCR5 receptor antagonist, from an ongoing, open-label extension of the Phase II VICTOR-E1 study in treatment-experienced HIV-infected patients.

15 Sep 2009

FDA approves Meda's ASTEPRO Nasal Spray

Meda Pharmaceuticals Inc. today announced that the US Food and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, for the treatment of the symptoms of seasonal and perennial allergic rhinitis (SAR and PAR). New ASTEPRO Nasal Spray 0.15% is the first nasal antihistamine to offer convenient once-daily dosing for patients who suffer from seasonal allergies.

2 Sep 2009

Study reveals that antibiotics used to treat a variety of bacterial infections could cause double vision

Highlights of September's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy), include a 2009 review by the Academy of the safety and efficacy of a widely used corneal transplant procedure and a warning about an unusual but serious reaction to systemic fluoroquinolones, a class of antibiotics used to treat a variety of bacterial infections.

2 Sep 2009

OHSU study reveals that fluoroquinolones may cause double vision

Highlights of September's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy), include a 2009 review by the Academy of the safety and efficacy of a widely used corneal transplant procedure and a warning about an unusual but serious reaction to systemic fluroquinolones, a class of antibiotics used to treat a variety of bacterial infections.

1 Sep 2009

Smell and taste disorders can be treated

When flowers aren’t fragrant and spicy foods don’t zing, the senses may be impaired. But don’t assume that diminished senses of taste and smell are due to aging, says the August issue of Mayo Clinic Women’s HealthSource.

13 Aug 2009